Business Context and Reporting Period
Company: Redhill Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: September 2015 (Notice of Annual General Meeting)
Meeting Date: October 29, 2015
Location: Tel Aviv, Israel
This filing serves as a proxy statement and notice for the Annual General Meeting of Shareholders. The primary agenda items involve the appointment of auditors and the re-election of directors. The filing references financial statements for the fiscal year ended December 31, 2014, but does not contain the financial statements themselves.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being available in the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2014.
- Outstanding Shares: 127,029,294 Ordinary Shares (as of September 25, 2015).
- Auditor Fees: Aggregate compensation for the year ended December 31, 2014, is noted as disclosed in the Form 20-F, but no specific amount is listed in this document.
Material Changes
No material financial changes or operational updates are detailed in this specific filing. The document focuses on corporate governance procedures for the upcoming shareholder meeting.
Guidance, Outlook, and Corporate Governance
Proposal 1: Appointment of Auditors
Shareholders are asked to appoint Kesselman & Kesselman (a member of PricewaterhouseCoopers International Limited) as independent auditors for the year 2015 and until the next Annual General Meeting. The Board and Audit Committee are authorized to determine fees.
Proposal 2: Election of Directors
The Board recommends the re-election of two directors for an additional three-year term:
- Dr. Kenneth Reed: Director since 2009; practicing dermatologist with over 25 years of clinical experience.
- Mr. Eric Swenden: Director since 2010; former CEO of Vandemoortele Food Group; designated as a financial and accounting expert under Israeli law.
Voting Requirements:
A quorum requires shareholders holding at least 25% of voting power. Resolutions require an affirmative vote of a majority of voting power represented at the meeting. The Board recommends a vote "FOR" all proposals.
Important Facts for Investors to Verify
- Review the Form 20-F for the fiscal year ended December 31, 2014, to obtain actual financial performance data (revenue, cash flow, debt) not included in this proxy statement.
- Confirm the Record Date for voting eligibility is September 25, 2015 (for Ordinary Shares) or September 22, 2015 (as noted in the Proxy Statement section for ADS holders).
- Verify the specific aggregate compensation paid to auditors for 2014 in the referenced Form 20-F.
- Note that shareholders holding shares through the Tel Aviv Stock Exchange must provide specific ownership certificates or use electronic voting systems to participate.